Below are the most recent publications written about "Ocular Hypertension" by people in Profiles.
-
Fan J, Liu J, Liu J, Chen C, Koutalos Y, Crosson CE. Evidence for ceramide induced cytotoxicity in retinal ganglion cells. Exp Eye Res. 2021 10; 211:108762.
-
Maa AY, McCord S, Lu X, Janjua R, Howell AV, Hunt KJ, Medert CM, Giangiacomo A, Lynch MG. The Impact of OCT on Diagnostic Accuracy of the Technology-Based Eye Care Services Protocol: Part II of the Technology-Based Eye Care Services Compare Trial. Ophthalmology. 2020 04; 127(4):544-549.
-
Maa AY, Medert CM, Lu X, Janjua R, Howell AV, Hunt KJ, McCord S, Giangiacomo A, Lynch MG. Diagnostic Accuracy of Technology-based Eye Care Services: The Technology-based Eye Care Services Compare Trial Part I. Ophthalmology. 2020 01; 127(1):38-44.
-
de Linde Henriksen M, Lim C, Sharp JL. Treatment of canine postoperative ocular hypertension with combined latanoprost 0.005% and atropine 1% ophthalmic solutions. Vet Ophthalmol. 2019 Jul; 22(4):448-461.
-
Alsarraf O, Fan J, Dahrouj M, Chou CJ, Yates PW, Crosson CE. Acetylation preserves retinal ganglion cell structure and function in a chronic model of ocular hypertension. Invest Ophthalmol Vis Sci. 2014 Oct 30; 55(11):7486-93.
-
Sharif NA, Katoli P, Scott D, Li L, Kelly C, Xu S, Husain S, Toris C, Crosson C. FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys. Drug Dev Res. 2014 Jun; 75(4):211-23.
-
Abdul Y, Akhter N, Husain S. Delta-opioid agonist SNC-121 protects retinal ganglion cell function in a chronic ocular hypertensive rat model. Invest Ophthalmol Vis Sci. 2013 Mar 11; 54(3):1816-28.
-
Trivedi RH, Boden JH, Mickler C, Wilson ME. Intraocular pressure elevation during early postoperative period after secondary intraocular lens implantation in children and adolescents. J Cataract Refract Surg. 2012 Sep; 38(9):1633-6.
-
Husain S, Abdul Y, Crosson CE. Preservation of retina ganglion cell function by morphine in a chronic ocular-hypertensive rat model. Invest Ophthalmol Vis Sci. 2012 Jun 28; 53(7):4289-98.
-
Harrison BA, Whitlock NA, Voronkov MV, Almstead ZY, Gu KJ, Mabon R, Gardyan M, Hamman BD, Allen J, Gopinathan S, McKnight B, Crist M, Zhang Y, Liu Y, Courtney LF, Key B, Zhou J, Patel N, Yates PW, Liu Q, Wilson AG, Kimball SD, Crosson CE, Rice DS, Rawlins DB. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem. 2009 Nov 12; 52(21):6515-8.